Related Experiment Video
Updated: Jul 16, 2026
04:42
Developing a Rat Model for Bipolar Disorder
Published on: May 2, 2025
Response to lithium prophylaxis: interaction between serotonin transporter and BDNF genes
Janusz K Rybakowski1, Aleksandra Suwalska, Maria Skibinska
1Department of Adult Psychiatry, Poznan University of Medical Sciences, Poznan, Poland. rybakows@wlkp.top.pl
Summary
Genetic variations in serotonin transporter (5HTTLPR) and brain-derived neurotrophic factor (BDNF) interact, influencing lithium response in bipolar disorder patients. This interaction impacts lithium prophylaxis efficacy.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Lithium is a key mood stabilizer for bipolar disorder.
- Serotonin transporter (5HTTLPR) and BDNF gene polymorphisms are linked to lithium efficacy.
- Understanding genetic interactions can optimize lithium treatment.
Purpose of the Study:
- To investigate the combined effect of 5HTTLPR and BDNF Val66Met polymorphisms on lithium response.
- To identify genetic markers predicting lithium prophylaxis outcomes.
- To explore epistatic interactions influencing treatment efficacy.
Main Methods:
- Study included 111 bipolar disorder patients on lithium carbonate for ≥5 years.
- Patients were genotyped for 5HTTLPR and BDNF Val66Met polymorphisms.
- Response to lithium was categorized into excellent, partial, and non-responders.
Main Results:
- A significant interaction between 5HTTLPR and BDNF genotypes and lithium response was observed.
- Patients with 'S' 5HTTLPR alleles and Val/Val BDNF genotype were more frequent in non-responders.
- Specific BDNF genotypes significantly altered lithium response in 'S' allele carriers.
Conclusions:
- Epistatic interaction between 5HTTLPR and BDNF influences lithium prophylaxis response.
- These genetic markers may predict lithium treatment outcomes in bipolar disorder.
- Further research is warranted to validate these findings for personalized medicine.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Human Genetics
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...